Rivaroxaban Did Not Reduce Cognitive Decline and Stroke/TIA in Young AF Patients: BRAIN-AF Trial
Key Points: In patients with atrial fibrillation, it remains unclear if anticoagulation therapy reduces the incidence of neurocognitive impairment In this randomized clinical trial, young patients who had atrial fibrillation…
QFR Did Not Meet Non-inferiority to FFR: FAVOR III Europe Trial
The FAVOR III Europe study aimed to investigate whether a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with an FFR-based strategy. The findings do not support the…
Orbital Atherectomy No Benefit Over Conventional Ballon Dilatation in Calcified Lesions: ECLIPSE Trial
The ECLIPSE trial evaluated orbital atherectomy (OA) vs conventional balloon dilatation (BA) in patients with de novo severely calcified lesions. The trial found no difference in target vessel failure (TVF)…
No Benefit of Colchicine in Large MIs: CLEAR SYNERGY Trial
Several randomized trials have shown reductions in MACE with colchicine in the treatment of coronary artery disease. The CLEAR SYNERGY (OASIS 9) trial showed that in patients with acute MI…
ApoA-I Infusions and Burden of Ischemic Events after Acute Myocardial Infarction
KEY POINTS: In this prespecified exploratory analysis of the AEGIS-II trial, the authors compare rates of recurrent myocardial infarction, stroke, and cardiovascular death up to 365 days among individuals who…
Apolipoprotein A-I infusions Lowers Risk of Recurrent CV Events in Patients With Baseline LDL-C ≥100 mg/dL
KEY POINTS: In this exploratory analysis of the AEGIS-II randomized control trial, the authors compare the rates of stroke, myocardial infarction and death at 90 days between patients with hyperlipidemia…
Improved Accuracy of HF Diagnosis with HFDetect-AI
Key Points: HFDetect-AI significantly improves the accuracy of diagnosing heart failure by predicting left ventricular dysfunction using standard echocardiographic measurements. The system was validated with a dataset comprising over a…
Pre-Hospital Pulse-Dose Glucocorticoid Did not Reduce Infarct Size in STEMI: PULSE-MI
Key Points: The PULSE-MI trial assessed the effects of pre-hospital pulse-dose glucocorticoid on final infarct size in STEMI patients, revealing no significant reduction compared to placebo. Despite the lack of…
ECLS-SHOCK: At One Year, ECMO Does Not Reduce Mortality in Acute MI-Related Cardiogenic Shock
Key Points: The 30-day ECLS SHOCK study demonstrated no benefit to up-front ECLS in the reduction of 30-day mortality in acute, infarct-related cardiogenic shock. At one year, there were similarly…
REC-CAGEFREE I: Drug Coated Balloon Fails To Achieve Non-Inferiority vs DES For De Novo Coronary Lesions
Key Points Drug-eluting stents are the standard of care for percutaneous coronary intervention of de novo coronary lesions but nevertheless have a risk of stent thrombosis and in-stent restenosis. Drug…
Plozasiran Lowered Triglyceride Levels and Pancreatitis in Persistent Chylomicronemia: PALISADE
Key Points: Familial chylomicronemia syndrome (FCS) is a clinically or genetically defined syndrome of extremely high plasma triglycerides due to failure of clearance of chylomicrons A novel siRNA therapeutic, plozasiran,…
Bailout GP IIb/IIIa inhibition in AMI with angiographic MVO failed to reduce the primary endpoint infarct size but decreased CMR-derived MVO: The REVERSE-FLOW trial
Key Points: Though primary PCI for coronary obstruction is first-line therapy in acute myocardial infarction (AMI), many patients experience impaired myocardial perfusion despite vessel patency (no-reflow phenomenon), worsening morbidity and…
AZALEA-TIMI 71 Sub-study: Periprocedural Bleeding Risk Very Low and Similar With Long-acting Factor XI Inhibitor Abelacimab vs Rivaroxaban
Key Points: Factor XI inhibitors have the potential to reduce thromboembolic events while minimizing major bleeding risks. Invasive procedures are frequent among patients with atrial fibrillation (AF), and the overall…
De-escalation to Ticagrelor Monotherapy Beneficial in Ischemic Events and Bleeding vs 12 months of DAPT: a Systematic Review and Individual Patient-Level Meta-analysis
KEY POINTS: Ticagrelor monotherapy was found to be non-inferior to 12 months of dual-antiplatelet therapy (DAPT) regarding major cardiovascular and cerebrovascular events (MACCE) in patients with acute coronary syndrome (ACS)…
Microvascular Resistance Reserve as a Potential Predictor of Angina in Moderate Coronary Stenoses.
Key Points: The Microvascular Resistance Reserve (MRR), a novel measurement, assess the vasodilator reserve capacity of the coronary microvasculature while eliminating resistance of epicardial stenoses This novel index has both…
Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody (FITTER)
Key Points: Adverse cardiovascular events can still occur from atherosclerotic events in non-culprit coronary arteries Evidence suggests lipid lowering therapy can significantly reduce the burden of disease in these segments,…
A Low-Dose Triple Single-Pill Combination Effective at Lowering Blood Pressure
Key Points: A single pill containing low doses of three different medicines induced significant and rapid reductions in blood pressure (BP) vs. dual therapy or placebo, with around 70% of…
OCCUPI: Optical Coherence Tomography (OCT) Outperforms Conventional Angiography in Guiding Revascularization for Complex Coronary Lesions
Key Points: In all-comer populations, coronary imaging guidance shows superior outcomes compared to conventional angiography in percutaneous coronary interventions (PCI). The OCCUPI trial demonstrated that OCT-guided PCI significantly improved clinical…
EARTH STEMI: Complete Revascularization Reduces Ischemic Events up to 4 years Among Older Patients with STEMI with Multivessel Disease
Key Points: Approximately 50% of patients with STEMI have multivessel disease but data regarding the benefit of complete versus culprit only revascularization are limited among older adults. The EARTH STEMI…
SENIOR-RITA: In Elderly Patients With NSTEMI, An Invasive Strategy Improved Clinical Outcomes Compared To Optimal Medical Therapy Alone
Key Points: Many older patients with NSTEMI do not receive coronary angiography during their index admission due to a high concern for complications and uncertainty regarding its benefits. SENIOR-RITA randomized…